EP Patent

EP3174533B1 — Oral disintegrating tablet

Assigned to Boehringer Ingelheim International GmbH · Expires 2019-09-11 · 7y expired

What this patent protects

Patent listed against azilsartan-kamedoxomil.

Drugs covered by this patent

azilsartan-kamedoxomil (AZILSARTAN KAMEDOXOMIL)

Patent Metadata

Patent number: EP3174533B1
Jurisdiction: EP
Classification: —
Expires: 2019-09-11
Drug substance claim: No
Drug product claim: No
Assignee: Boehringer Ingelheim International GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.